{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T17:56:01Z","timestamp":1774115761813,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.clml.2019.05.006","type":"journal-article","created":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T11:03:03Z","timestamp":1557745383000},"page":"e526-e531","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Generic Imatinib in Chronic Myeloid Leukemia Treatment: Long-Term Follow-up"],"prefix":"10.1016","volume":"19","author":[{"given":"Irena","family":"\u0106ojba\u0161i\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lana","family":"Ma\u010dukanovi\u0107-Golubovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miodrag","family":"Vu\u010di\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u017darko","family":"\u0106ojba\u0161i\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.05.006_bib1","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.3324\/haematol.2009.010629","article-title":"High rates of durable response are achieved with imatinib after treatment with interferon-alfa plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial","volume":"94","author":"Guilhot","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.05.006_bib2","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs. STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukaemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.05.006_bib3","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","article-title":"The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts","volume":"121","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.05.006_bib4","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.3109\/10428194.2014.921299","article-title":"Generic imatinib: the real-deal or just a deal?","volume":"55","author":"Mathews","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2019.05.006_bib5","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3109\/10428194.2014.947609","article-title":"The efficacy and tolerability issue of generics of imatinib in the treatment of chronic myeloid leukemia: do generics really jeopardize patient safety?","volume":"56","author":"Eskazan","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2019.05.006_bib6","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1177\/1078155215570766","article-title":"Generic imatinib in the treatment of chronic myeloid leukemia: Cerrahpasa experience","volume":"22","author":"Eskazan","year":"2016","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.clml.2019.05.006_bib7","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.05.006_bib8","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/leu.2015.29","article-title":"Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia","volume":"29","author":"Cross","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.05.006_bib9","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/jps.22772","article-title":"Conformational polymorphism on imatinib mesylate: grinding effects","volume":"101","author":"Grillo","year":"2012","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.clml.2019.05.006_bib10","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.clinthera.2009.10.009","article-title":"Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers","volume":"31","author":"Parrillo-Campiglia","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.clml.2019.05.006_bib11","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.clml.2016.04.003","article-title":"Comparison of branded and generic imatinib plasma concentrations in patients with chronic myelogenous leukemia: unicentric study","volume":"16","author":"Ostojic","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2019.05.006_bib12","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.3109\/10428194.2014.893302","article-title":"Deleterious effects of non-branded versions of imatinib used for the treatment of patients with chronic myeloid leukemia in chronic phase: a case series on an escalating issue impacting patient safety","volume":"55","author":"Saavedra","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2019.05.006_bib13","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.3109\/10428194.2014.904508","article-title":"Prospective single-center study of chronic myeloid leukemia in chronic phase: switching from branded imatinib to a copy drug and back","volume":"55","author":"Alwan","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2019.05.006_bib14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4999\/uhod.1111","article-title":"Generic imatinib mesylate is as effective as original Glivec in the clinical management of CML","volume":"4","author":"Malkan","year":"2015","journal-title":"UHOD"},{"key":"10.1016\/j.clml.2019.05.006_bib15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/bjh.12937","article-title":"First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate","volume":"167","author":"Eskazan","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.05.006_bib16","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.3109\/10428194.2014.905774","article-title":"The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia","volume":"55","author":"Eskazan","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2019.05.006_bib17","first-page":"125","article-title":"A\u00a0multicenter, prospective study\u00a0on efficacy and safety of imatinib generics; a report from Polish Adult\u00a0Leukemia Group Imatinib Generics Registry","volume":"92","author":"Sasha","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2019.05.006_bib18","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.clml.2017.02.001","article-title":"The efficacy of generic imatinib as first and second-line therapy: 3-year follow-up of patients with chronic myeloid leukemia","volume":"17","author":"Islamagi\u0107","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2019.05.006_bib19","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries","volume":"29","author":"Hoffman","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.05.006_bib20","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/leu.2015.152","article-title":"Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib","volume":"29","author":"Castagenetti","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.05.006_bib21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.clml.2017.05.006","article-title":"Generic imatinib in chronic myeloid leukemia: survival of the cheapest","volume":"17","author":"Danthala","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019302058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019302058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:32:59Z","timestamp":1761870779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265019302058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S2152265019302058"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.05.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Generic Imatinib in Chronic Myeloid Leukemia Treatment: Long-Term Follow-up","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}